Chemoradiation therapy in nonsmall cell lung cancer

Current Opinion in Oncology

Volumn 23, Issue 2, 2011, Pages 140-149

  Baas, Paul ^a   Belderbos, Jose S A ^b   Van Den Heuvel, Michel ^a  

^a Department of Thoracic Oncology ^*  (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

chemoradiation therapy; nonsmall cell lung cancer; stage III; targeted agents

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; ARTICLE; BRONCHOPLEURAL FISTULA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIOSENSITIZATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS;

EID: 79952004943     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328341eed6     Document Type: Article

References (71)

1. Petrovich Z, Stanley K, Cox JD, Paig C. Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer 1981; 48:1335-1340. (Pubitemid 11042584)
2. Schaake-Koning C, Van den Boogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non small-cell lung cancer. N Engl J Med 1992; 326:524-530.
3. Behzadi A, Ung Y, Lowe V, Deschamps C. The role of positron emission tomography in the management of nonsmall cell lung cancer. Can J Surg 2009; 52:235-242.
4. Hochstenbag MM, Twijnstra A, Hofman P, et al. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer 2003; 42:189-193. (Pubitemid 37268029)
5. Van Rens MT, de la Riviè re AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117:374-379. (Pubitemid 30111585)
6. Chen KY, Chen JH, Shih JY, et al.Octogenarians with advanced non small cell lung cancer: treatment modalities, survival and prognostic factors. J Thorac Oncol 2010; 5:82-89.
7. Casas F, Kepka L, Agarwal JP, et al. Radiochemotherapy in the elderly with lung cancer. Expert Rev Anticancer Ther 2009; 9:1405-1411.
8. De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009; 20:98-102.
9. Phernambucq EC, Spoelstra FO, Verbakel WF, et al. Outcomes of concurrent chemoradiotherapy in patients with stage III non small-cell lung cancer and significant comorbidity. Ann Oncol 2010. [Epub ahead of print]
10. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radio-chemotherapy in locally advanced non small-cell lung cancer. J Clin Oncol 2010; 28:2181-2190.
11. O'Rourke N, Roqué I, Figuls M, et al. Concurrent chemoradiotherapy in non small cell lung cancer. Cochrane Database Syst Rev 2010:CD002140.
12. Belderbos JS, Heemsbergen WD, De Jaeger K, et al. Final results of a Phase I/II dose escalation trial in non small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:126-134. (Pubitemid 44175671)
13. Liao ZX, Komaki RR, Thames HD Jr, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:775-781.
14. Bradley JD, Moughan J, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non small-cell lung cancer: RTOG 0117. J Clin Oncol 2010; 28:2475-2480.
15. Stinchcombe TE, Morris DE, Lee CB, et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB nonsmall cell lung cancer. J Thorac Oncol 2008; 3:250-257. (Pubitemid 351654324)
16. Lee CB, Stinchcombe TE, Moore DT, et al. Late complications of high-dose (>/66Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III nonsmall cell lung cancer. J Thorac Oncol 2009; 4:74-79.
17. Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12:539-547. (Pubitemid 16081614)
18. Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable nonsmall cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993; 27:493-498. (Pubitemid 23331113)
19. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in nonsmall- cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997. 350: 161-165. (Pubitemid 27303621)
20. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/ unresectable nonsmall-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005; 63:324-333. (Pubitemid 41317147)
21. Yorke ED, Jackson A, Rosenzweig KE, et al. Correlation of dosimetric factors and radiation pneumonitis for nonsmall-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 2005; 63:672-682. (Pubitemid 41400051)
22. Sonke JJ, Belderbos J. Adaptive radiotherapy for lung cancer. Semin Radiat Oncol 2010; 20:94-106.
23. Dillman RO, Jerndon J, Seagron SL Jr, et al. Improved survival in stage III nonsmall-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1175-1177.
24. Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117:358-364.
25. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25:1698-1704. (Pubitemid 46797950)
26. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23:5910-5917.
27. Scagliotti GV, Szczesna A, Ramlau R, et al. Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non small-cell lung cancer. Br J Cancer 2006; 94:1375-1382. (Pubitemid 43772269)
28. Kocak M, Ozkan A, Mayadagli A, et al. Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non small-cell lung cancer: a single-institution review of two different regimens. Clin Lung Cancer 2009; 10:124-129.
29. Gandara D, Chansky K, Albain K, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004-2010. (Pubitemid 46606390)
30. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26:5755-5760.
31. Bastos BR, Hatoum GF, Walker GR, et al. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non small cell lung cancer. J Thorac Oncol 2010; 5:533-539.
32. Movsas B, Langer CJ, Ross HJ, Wang L, et al. Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non small cell lung cancer. J Thorac Oncol 2010; 5:673-679.
33. Jain AK, Huges RS, Sandler AB, Dowlati A, et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non small cell lung cancer. J Thorac Oncol 2009; 6:722-727.
34. Vokes EE, Senan S, Treat JA, et al. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009; 10:193-198.
35. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26:2450-2456.
36. Rigas JR. Docetaxel, carboplatin and thoracic radiotherapy in unresectable stage III non small cell lung cancer (NSCLS): a safety report of the first .100. patients treated with this concurrent chemoradiation as part of a multicenter web-based trial, D0410: PD4-1-5. J Thorac Oncol 2007; 2: S449.
37. Rigas JR, Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2007; 2 (Suppl 2):S77-S85.
38. O'Rourke N, Macbeth F. Is concurrent chemoradiation the standard of care for locally advanced nonsmall cell lung cancer? A review of guidelines and evidence. Clin Oncol (R Coll Radiol) 2010; 22:347-355.
39. Parashar B, Edwards A, Mehta R, et al. Chemotherapy significantly increases the risk of radiation pneumonitis in radiation therapy of advanced lung cancer. Am J Clin Oncol 2010. [Epub ahead of print]
40. Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III nonsmall cell lung cancer. Lung Cancer 2004; 43:309-316. (Pubitemid 38224151)
41. Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III nonsmall-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17:4-11. (Pubitemid 29022371)
42. Belderbos J, Uitterhoeve L, van Zandwijk N, et al. Randomized trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007; 43:114-121. (Pubitemid 46054477)
43. Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010; 28:3739-3745.
44. Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010; 28:3299-3306.
45. Provencio M, Sanchez A, Garrido P, et al. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 2010; 11:91-97.
46. Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. Eur J Cancer 2001; 37 (Suppl 4):S16-S22. (Pubitemid 32938125)
47. Lin H, Jiang J, Liang X, et al. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010; 70:57-62.
48. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-1531.
49. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28:911-917.
50. Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat 2010; 13:29-43.
51. Hallqvist A, Wagenius G, Rylander H, et al. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite-A phase II study from the Swedish Lung Cancer Study Group. Lung Cancer 2010. [Epub ahead of print]
52. Hughes S, Liong J, Miah A, et al. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III nonsmall cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 2008; 3:648-651. (Pubitemid 351787311)
53. Van den Heuvel MM. Cetuximab in combination with concurrent chemoradiotherapy (CRT) in locally advanced nonsmall cell lung carcinoma (NSCLC): a feasibility study [abstract 7540]. J Clin Oncol 2009; 27:15s.
54. Govindan R, Bogart J, Vokes EE, et al. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable nonsmall cell lung cancer: CALGB 30407. J Clin Oncol 2009; 27 (Suppl 15):A-7505.
55. Blumenschein GR. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non small cell lung cancer (NSCLC): a report of the 2-year and median survival (MS) for the RTOG 0324 trial [abstract 7516]. J Clin Oncol 2008; 26.
56. Jensen AD, Mü nter MW, Bischoff H, et al. Treatment of nonsmall cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer 2006; 6:122.
57. O'Byrne KJ. First-cycle rash as a clinical marker in patients with advanced nonsmall cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: efficacy by histology [abstract 7556]. J Clin Oncol 2010; 28:15s.
58. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551.
59. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440.
60. Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non small cell lung or esophageal cancer. Clin Cancer Res 2007; .13. (2 Pt 1):515-522. (Pubitemid 46225357)
61. Brade AM. A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b non small cell lung cancer (NSCLC) [abstract 7087]. J Clin Oncol 2010; 28:s15.
62. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
63. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non squamous, non small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
64. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28:43-48.
65. Socinski MA. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non small cell lung cancer (NSCLC) [abstract 7517]. J Clin Oncol 2008; 26.
66. Socinski MA. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non small cell lung cancer (NSCLC) [abstract 7528]. J Clin Oncol 2009; 27:s15.
67. Ready N, Jänne PA, Bogart J, et al. Chemoradiotherapy and gefitinib in stage III nonsmall cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGBstratified phase II trial. J Thorac Oncol 2010; 5:1382-1390.
68. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374:379-386.
69. Friedel G, Budach W, Dippon J, et al. Phase II trial of a trimodality regimen for stage III non small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 2010; 28:942-948.
70. Kappers I, Belderbos JS, Burgers JA, et al. Non small cell lung carcinoma of the superior sulcus: favorable outcomes of combined modality treatment in carefully selected patients. Lung Cancer 2008; 59:385-390. (Pubitemid 351335104)
71. Van Elmpt W, Petit S, van der Sal A, et al. Biological Target Volume (BTV) boost phase II study on dose-escalation of the high uptake FDG-PET regions inside the primary tumour for NSCLC: the treatment planning strategy. Radiother Oncol 2010; 94 (Suppl 1):S11.